A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer-Reference-Cited by-同舟云学术

A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer

Published:2015-11-12 Issue:1 Volume:77 Page:147-153
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

AL-Tweigeri Taher, ,AlSayed Adher,Alawadi Shafika,Ibrahim Mohamed,Ashour Wafaa,Jaafar Hassan,Abulkhair Omalkhair,AL-Abdulkarim Huda,Khalid Hassan,Ajarim Dahish

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2906-5.pdf

Reference44 articles.

1. Von Minckwitz G, Kaufmann M, Kuemmel S, for the GBG and AGO-B Study Groups et al (2011) Correlation of various pathologic complete response (pCR) definitions with long term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J clin Oncol 29(suppl):1028

2. Montagna E, Bagnardi V, Rotmensz N et al (2010) Pathologic complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 124:689–699

3. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative Docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocols B-27. J Clin Oncol 24:2019–2027

4. Sachelaria I, Grossbard MI, Chadha M et al (2006) Primary systemic therapy of breast cancer. Oncologist 11:564–589

5. Kaufmann M, Von Minckwitz G, Mamounas EP et al (2012) Recommendation from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01

2. Understanding Breast Cancer Oncology: The Need for Mastectomy and Axillary Staging;Prepectoral Breast Reconstruction;2023

3. Diseases with the highest mortality;Phytochemical Nanodelivery Systems as Potential Biopharmaceuticals;2023

4. Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE;Clinics and Practice;2022-11-07

5. Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis;Computational and Mathematical Methods in Medicine;2021-12-31